Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab PK and Safety Study in Healthy Chinese Participants
NCT05140200Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of depemokimab in asthma (2 arms), sponsored by GSK. Primary endpoints: Area Under the Plasma Concentration-Time Curve, Maximum Observed Plasma Concentration and 6 more. Started Dec 2021; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05140200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140200.